Can a Symptom Tracker Predict a Flare?

Not in the way the question usually means. No app, wearable or diary can currently tell you that your flare is coming next week with a hit rate you could plan around. What the research does show is narrower and still useful: in Crohn's disease and ulcerative colitis, a few signals shift on average in the weeks before flares, and a raised faecal calprotectin in remission raises the odds of a later flare by a factor of two to three. In IBS, we could not find any tracked signal that has been shown to forecast a bad spell.

That gap between "changes before flares, averaged across 300 people" and "will warn me personally" is the whole story of this article. It is also where most of the confident marketing lives. This is written for the person who has been told their ring, watch or app can "catch flares early" and wants to know how much weight that claim can bear, and for the person asking the sharper question underneath it: if my tracker cannot predict a flare, why am I logging at all?

A note on method. When we say we found no study on something, that reflects our searching of PubMed and Europe PMC for this article, not proof that none exists.

The short answer: a tracker can raise a flag, it cannot make a forecast

A flag says "something has changed, look closer". A forecast says "a flare is coming, and here is how confident I am". The first is achievable with a simple daily log. The second needs something nobody has published for consumer use yet: evidence that a specific alert, applied to one person, is right often enough and early enough to be worth acting on.

Two different things get blurred together in the way apps and forum posts talk about this:

1. Association before the event. Researchers line up everyone's data by the date their flare started, then look backwards. If heart rate, sleep or calprotectin is on average different in the weeks before, the signal "changes before flares". This is what most of the evidence shows.
2. Prediction going forwards. You stand at today, with no idea whether a flare is coming, and ask whether today's reading tells you. That depends on how often the signal fires when no flare follows, and on how common flares are in the first place.

A signal can be excellent at the first and poor at the second. A developer in one colitis thread described building an app that uses watch data for "forecasting", citing Mount Sinai research showing wearable data can flag changes weeks before a flare. That poster disclosed that they built the app, which is to their credit, and the research they pointed to is real. But the research, as far as we could read it, is the first kind of evidence. The app is selling the second.

What "predict" would actually have to mean

Prediction is a claim about three numbers, and you need all three before an alert means anything.

• Lead time. How far ahead does the signal move? A warning on the morning the blood appears is detection, not prediction.
• Hit rate (sensitivity). Of the flares that happened, how many did the signal catch in advance?
• False-alarm rate (1 minus specificity). Of the stretches with no flare, how often did the signal fire anyway?

Then there is a fourth number that is not about the signal at all: how common flares are over the window you care about. Statisticians call the resulting figure the positive predictive value, the chance that an alert is real, and it falls sharply when the thing being predicted is uncommon, even for a decent test (Altman 1994).

A worked example with real numbers

A meta-analysis of six prospective studies (672 people) found that a calprotectin measured in remission predicted later relapse with a pooled sensitivity of 78% and specificity of 73% (Mao 2012). Those are respectable numbers for a single stool test. Here is what they mean in practice, using an illustrative relapse rate over the follow-up window:

The relapse rates in the first column are ours, chosen to show the effect; the sensitivity and specificity are Mao's. The point survives any reasonable choice: at realistic flare rates, a large share of warnings are not followed by a flare in that window, and roughly one flare in five slips through unflagged.

Now imagine the same arithmetic for a daily wearable alert. The chance that a flare begins on any given day is tiny compared with the chance over a year. A signal with a false-alarm rate that sounds low per day still produces many false alarms over months of wear. We could not find a published false-alarm rate per day or per week of wear for any IBD wearable model, and that is the number you would need.

The strongest early signal is not in your app: calprotectin

The most evidence for any warning signal in IBD belongs to a stool test, not a symptom. Faecal calprotectin measures a protein released by white cells in an inflamed gut lining. It can rise while you still feel fine, which is exactly what makes it a candidate early signal. Our guide to high calprotectin with no symptoms covers why the two come apart, and what calprotectin levels mean in ulcerative colitis covers assays and thresholds. Here the question is narrower: how well does it forecast?

Pooled accuracy. Beyond Mao's six-study pooling above, a later meta-analysis limited to adults with ulcerative colitis in remission pooled 14 studies (1,110 people) and found a sensitivity of 75% and specificity of 77% for predicting clinical relapse, with an area under the curve of 0.82 (Li 2019). Mao found the predictive value similar in UC and Crohn's, better in colonic and ileocolonic Crohn's than across Crohn's as a whole, and could not assess isolated small-bowel Crohn's for lack of data (Mao 2012). If your Crohn's lives in the small bowel only, the evidence for calprotectin as an early warning is thin.

Lead time. One prospective study measured calprotectin every four weeks in 87 people with ulcerative colitis in remission on infliximab. Of the 13 who relapsed, calprotectin was already significantly higher, median above 300 mg/kg, three months before the flare. Two consecutive readings above 300, a month apart, was the best predictor: specificity 100%, sensitivity 61.5% (De Vos 2013). Read the sensitivity as a count: 61.5% of 13 is 8. Five of the thirteen relapses were not preceded by that signal. And a 100% specificity from a study of 87 people, 13 of whom relapsed, is encouraging but rests on small numbers. We could not read a funding or conflict statement for this study.

A competitor app's blog, reviewed while researching this piece, says a rising calprotectin "often predates a clinical flare by weeks", citing the 2019 meta-analysis and attributing it to the Journal of Gastroenterology and Hepatology. That meta-analysis is in Mediators of Inflammation, and its abstract reports accuracy, not a lead time. The weeks-to-months lead-time evidence exists, De Vos is an example, but it does not come from that paper.

Absolute risk, which is what you actually want. The largest recent study, PREdiCCt, followed 2,629 people across 47 UK centres who reported being in remission, for a median of 4.1 years. Compared with a baseline calprotectin under 50 µg/g, a reading over 250 carried an adjusted hazard ratio of 3.25 for an objective flare, meaning a flare confirmed by bloods or calprotectin and needing treatment escalation (Constantine-Cooke 2026). Translated into two-year absolute risks in the full text:

That table is the most honest answer to "can a number predict my flare" that exists. A high reading roughly triples the risk. And still, about three in four people with Crohn's and about two in three with UC who had that high reading did not have an objective flare in the following two years. PREdiCCt was funded by charities and public bodies: Cure Crohn's Colitis, Crohn's & Colitis in Childhood, the Scottish Chief Scientist Office and UK Research and Innovation.

The practical upshot is what the American Gastroenterological Association already suggests for people with UC in symptomatic remission: monitor with biomarkers and symptoms together rather than symptoms alone (Singh 2023). That is a monitoring strategy run by your IBD team, with a stool sample on a schedule. It is not something your phone can do from how you feel.

What the wearable studies actually found

This is the research behind most "your watch can catch flares" claims, so it deserves a careful read.

The Mount Sinai physiology study. Researchers enrolled 309 people with IBD across 36 US states who answered daily disease-activity questions and wore an Apple Watch, Fitbit or Oura ring. Heart rate and resting heart rate were higher, and daily steps fewer, during inflammatory flares; daily rhythms in heart rate variability differed between flare and remission; and heart rate variability, heart rate and resting heart rate helped separate people whose symptoms came with inflammation from those whose symptoms did not. Crucially for this question: heart rate variability, heart rate, resting heart rate, steps and oxygenation were significantly altered up to seven weeks before both inflammatory and symptomatic flares (Hirten 2025).

That is a genuinely interesting result, published in a top journal, funded by a US National Institutes of Health grant. It is also, by the authors' own conclusion, evidence of feasibility to monitor and predict IBD activity. We could read only the abstract: Europe PMC's full-text service returned server errors and PubMed Central was not reachable from our tools. The abstract says mixed-effect logistic regression was used to assess predictive ability, but it does not give a per-person alert accuracy, a false-alarm rate or a threshold. So we cannot tell you how often a real-time alert built on this would be right, and we would be suspicious of anyone who quotes you one without citing where it comes from. We were also unable to read the paper's full conflict-of-interest statement; PubMed carries only its closing line.

The sleep study. The same group followed 101 people for a mean of about 228 nights. Periods of active inflammation came with a smaller share of REM sleep and more light sleep. Symptomatic flares on their own, without inflammation, did not change sleep architecture. The share of time in deep and light sleep changed at significantly different rates in the 45 days before and after flares (Hirten 2026). As reported by Medscape, the REM difference during inflammation was about 20% against about 21.6% of sleep time. That is a difference averaged across many nights and many people. A consumer device's night-to-night variation in estimated REM can easily be larger than that, which is one reason a single bad night on your ring tells you very little.

The older sleep evidence. In a large US online cohort, people whose Crohn's was in remission and who reported impaired sleep had twice the odds of active disease six months later (adjusted odds ratio 2.00, 95% CI 1.45 to 2.76, among 1,291 people). In ulcerative colitis there was no such association (odds ratio 1.14, 95% CI 0.75 to 1.74) (Ananthakrishnan 2013). So "bad sleep comes before flares" has some support in Crohn's, and none in this study for UC. It also cannot tell you which way the arrow points: early inflammation may be what is disturbing the sleep.

The forum version of the same finding. People describe this in their own words. In a Crohn's thread about wearables, several people said their resting heart rate climbs during a bad flare and takes longer to settle after exercise; one pointed to the Truelove and Witts colitis severity criteria, which include heart rate; another said it happened to them but they knew of no studies, which in 2022 was fair. In a thread asking about the Oura ring, one person said their heart rate variability goes up heading into a flare, and another said theirs goes down. Others said the device picked up a cold or flu a day before symptoms, which is plausible and not the same thing as a flare. And one long-term wearer summed up what several hinted at: if they feel terrible they sleep badly and their stress score rises, "but that's not a predictor".

That last comment is the most useful thing in either thread. A signal that moves with feeling unwell is a detector, not a forecaster. And the up-versus-down disagreement is a reminder that any personal rule has to be built from your own data, not borrowed.

Can a symptom score predict anything?

Yes, in a narrow, clinic-shaped way.

The Oxford TrueColours team built a calculator to predict whether a person with ulcerative colitis would need their treatment escalated at their next outpatient appointment. Of ten candidate items, four predicted escalation (SCCAI, IBD-Control-8, calprotectin and platelets). For practicality they chose a model using only the two patient-entered questionnaires. In a validation cohort of 538 patients, a 5% threshold correctly flagged 343 of 388 escalations (88%) and correctly cleared 274 of 484 non-escalations (57%) (Matini 2023).

Run the same arithmetic as before. The calculator flagged 343 true escalations plus 210 appointments that did not end in escalation, so about 62% of flags were right. Of the 319 it cleared, 274, about 86%, were correctly cleared. That is a sensible tool for deciding which clinic slots need a doctor, which is what it was built for. It is not a flare forecast, and it predicts a decision at an appointment, not an event on a date. One loose end: the abstract's two counts add to 872 appointments, while the validation cohort is described as 1,188 appointments, and the abstract does not say what happened to the other 316. We could not read the full text to reconcile it. The work was supported by NIHR and the Oxford Biomedical Research Centre, and its PubMed grant list also names AbbVie, Buhlmann Laboratories (which makes calprotectin tests), Janssen, Lilly, Pfizer and Takeda. The IBD tracker app guide covers this calculator in its wider context.

If you want your own symptom data to carry weight, log it in a form that maps onto a score your team already uses: PRO-2 for ulcerative colitis or the Harvey-Bradshaw Index for Crohn's.

Do monitoring programmes stop flares?

Not on the evidence so far. They change how care is delivered, which is valuable, but not how often people flare.

myIBDcoach. In a pragmatic randomised trial in four Dutch hospitals, 909 outpatients were assigned to a telemedicine system that monitored disease activity or to standard care for 12 months. The telemedicine group had fewer outpatient visits (1.55 against 2.34 on average) and fewer hospital admissions (0.05 against 0.10). The mean numbers of flares, steroid courses, emergency visits and surgeries did not differ between groups, and patient-rated quality of care was high in both (de Jong 2017). The trial was funded by Maastricht University Medical Centre and Ferring, a company that makes IBD medicines, and it was unblinded, as a trial like this has to be.

TELE-IBD. A US trial randomised 348 people with IBD who had worsening symptoms in the previous two years to text-message monitoring every other week, weekly, or standard care. Disease activity and quality of life improved in all groups, and the changes did not differ significantly between them. Weekly telemonitoring came with fewer IBD-related hospitalisations but more tests, phone calls and electronic contacts (Cross 2019).

Put those two side by side and the honest reading is: remote monitoring can reorganise care safely, catch problems through a different door, and in one trial reduce admissions, but neither trial showed it reduced flares. A home app with no clinician on the other end is a weaker version still. None of that means logging is pointless. It means the benefit is in response, not foresight.

IBS is a different question, and the answer is harder

Everything above leans on inflammation: a biological process that can build quietly, leak calprotectin into stool and nudge heart rate, before it becomes symptoms. IBS does not have that. There is no inflammation marker to monitor, and the American College of Gastroenterology uses calprotectin in suspected IBS with diarrhoea only to rule out IBD, not to track IBS (Lacy 2021). What counts as an IBS flare at all is already slippery, which our guide to how you know your IBS is flaring takes apart.

The best-designed studies of IBS symptoms over time sample people many times a day on their phones, which avoids memory bias. Their findings cut against the idea of a lead signal:

• Stress and pain move together, in the moment. In 37 people with IBS rating stress and abdominal pain at up to ten random moments a day for a week, each one-point rise in stress went with about a 0.10-point rise in pain at the same moment. But stress at the previous sampling moment did not predict pain at the next one, and pain did not predict later stress either (Vork 2020).
• Day-to-day stress barely tracked day-to-day symptoms within the same person. In 181 women with IBS who logged stress and gut symptoms daily for a month, people with higher average stress had worse average symptoms, but within each woman, the day-to-day ups and downs of stress showed little relationship with the day-to-day ups and downs of symptoms (Hertig 2007).
• Memory makes it look more predictable than it is. End-of-day diaries recorded abdominal pain about 0.4 points higher, on a 1 to 5 scale, than the average of in-the-moment ratings over the same days, and the authors noted a tendency to report peak rather than average pain (Mujagic 2015). A story of "it built up over three days" is sometimes a story memory wrote afterwards.

One r/ibs post charted a month of anxiety and abdominal pain from an app, with the two lines rising and falling together. The first reply asked the right question: is the anxiety causing the pain, or the pain causing the anxiety? Another reader thought the anxiety line turned first. Two lines on a chart that move together cannot answer that, and the real-time studies above suggest that within a day, neither reliably leads.

We could not find a study that tested whether any tracked signal forecasts an IBS flare days ahead. An older r/ibs meme suggested astrology was as good a way as any to predict which foods cause which symptoms. That is a joke, and also, for forecasting specifically, not far from where the evidence stands. For the stress question in more depth, see whether stress can cause an IBS flare. For why a food log so often returns nothing, see why a food diary shows no pattern.

What an IBS tracker can do is describe: how often bad days happen, how long they last for you, whether they cluster around your period, poor sleep or particular meals, and whether a treatment you are trying is shifting the baseline. That is worth having. It is not a forecast.

The warning signs people describe, and how much to trust them

Forums are full of personal prodromes: exhaustion, needing far more sleep, more wind or a change in its smell, mouth ulcers, joint aches, a run of poor sleep, a slightly raised resting heart rate, feeling cold or feverish. Our guide to knowing when ulcerative colitis is flaring goes through the early signals colitis forums describe and which have some basis; the Crohn's equivalent is in how to tell if you are in a Crohn's flare. Two cautions apply to all of them.

Almost every early sign is non-specific. Fatigue, poor sleep, a faster pulse and low mood rise with colds, infections, stress, heat, alcohol, steroids and ordinary bad weeks. A signal that fires for all of those will fire far more often than you flare. That is the false-alarm problem from the table above, happening in your own body.

Some "warning signs" are something else. One question in the research brief for this article was whether a metallic taste in the mouth warns of a flare. We found no research on that. In the one colitis thread we read about it, the poster was taking methotrexate alongside an infliximab biosimilar and believed the taste came from methotrexate, saying it was a listed side effect. We checked two US methotrexate tablet labels on DailyMed and did not find taste change in either, so we cannot confirm that; labels differ by country and formulation. Either way, a new symptom on a new medicine is a question for your IBD team or pharmacist, not a forecast. Likewise, night sweats and fever deserve their own attention rather than being filed as a flare prodrome; see Crohn's disease and night sweats.

The useful move is to treat your remembered prodrome as a hypothesis and test it, which the worked example below does.

Does watching your data too closely make things worse?

It can, for some people, and the evidence points in two directions.

Logging itself is not usually the problem. In a trial where 91 people with chronic pain were randomised to different intensities of electronic diary reporting over two weeks, there was little sign that frequent reporting changed pain levels or weekly recall of pain, and compliance was 94% or better (Stone 2003). That was chronic pain, not IBD or IBS, but it is reassuring that writing things down does not by itself make them worse.

Alerts and checking can be. In a propensity-matched study of 172 people with atrial fibrillation, the 83 who used a wearable reported more symptom monitoring and preoccupation and more treatment concerns than non-users, 20% of wearable users experienced anxiety and always contacted their doctor in response to an irregular rhythm notification, and wearable users used more AF-related healthcare (Rosman 2024). That is a heart-rhythm population and a retrospective study, so it shows association, not cause. But it is the closest evidence we found to what a "flare risk" notification might do to a worried person.

In IBS, the worry is part of the illness. Among 306 people with IBS, gut-specific anxiety, the fear and hypervigilance about gut sensations measured by the Visceral Sensitivity Index, was the strongest predictor of how severe GI symptoms were in a regression model (Jerndal 2010). A tool that invites you to check your gut hourly for signs of trouble is feeding the thing most strongly linked to how bad the symptoms feel.

If you notice checking your numbers is leaving you more anxious, a few changes usually help: log once a day at a fixed time, look at trends weekly rather than daily, and switch off any "risk" or "readiness" notifications. Our guide to IBS and health anxiety goes further into the checking loop and what treatment helps.

So what is a tracker for, if not prediction?

Three jobs, all of them real.

1. Detecting a sustained change sooner than memory would. A flare rarely announces itself on day one. It creeps: one extra movement a day, a looser Bristol type, an urgency episode that becomes three. A daily log against your own baseline shows that drift within a week or two, where memory tends to normalise it. That is detection, and it is the thing monitoring programmes like myIBDcoach turn into fewer clinic visits and admissions.

2. Turning feelings into numbers your team can act on. "I think it's starting again" is hard for anyone to respond to. "Movements per day have gone from a baseline of two to five over ten days, with blood on four of them" gets you a calprotectin request or an earlier review. Our guide to what to track in an IBD symptom diary covers the fields, and the symptom tracker to take to your doctor covers the one-page handover.

3. Testing your own prodrome. After two or three flares, a log can show whether the signs you remember actually came first, how early, and how often they came without a flare. That is the only kind of "prediction" we can honestly recommend: a personal rule, tested against your own history, used to prompt a call rather than a treatment change.

This is also where Clairop fits, and where it does not. It does not predict flares, and it does not claim to. It calculates PRO-2 or the Harvey-Bradshaw Index from answers you have already given, shows movements per day against your own baseline, and puts the trend, days with blood, overnight episodes and adherence on a one-page report for your appointment. Detection and documentation, nothing more.

A worked example: testing a personal warning rule honestly

Ana is a hypothetical example, built to show the method. She has Crohn's colitis, in remission on maintenance treatment. She is convinced that two weeks of poor sleep and a resting heart rate a few beats above her usual always come before her flares. She has 18 months of wearable data and a daily log, and three flares confirmed by her IBD team in that time.

She writes her rule down before looking: "resting heart rate at least 5 beats above my 30-day average for seven days in a row, plus at least four poor-sleep nights in that week". Then she scrolls through all 18 months and counts.

So her rule caught two of three flares, and of the seven times it fired, two were followed by a flare: about 29%. That is still useful. It tells her that when the rule fires and she has no cold and no night shifts to explain it, that is a reasonable prompt to message her IBD nurse and ask whether a calprotectin is worth doing. It also tells her not to panic, not to change anything herself, and that one flare in three will arrive without warning, so the rule is not a reason to ignore symptoms when they come.

Notice what she did not do: she did not start from the flares and look backwards for anything that changed. Look backwards through 18 months of data from three chosen dates and something will always seem to have changed. Writing the rule down first, and counting the false alarms, is what makes it a test rather than a story.

How to read an app's "flare risk" claim

Before you trust or pay for a prediction feature, ask:

1. What was it validated against? A flare confirmed by calprotectin, bloods or a scope, or a flare the user reported? The wearable research found some signals separated inflamed from non-inflamed symptoms, which matters because symptoms alone mislead in both directions.
2. In whom? People on the same kind of treatment, with the same disease, wearing the same device? Results from a US research cohort may not carry over to a different device or population.
3. How far ahead, and how often right? You want lead time, the share of flares caught and the share of alerts that were false. An area-under-the-curve figure alone does not tell you how many false alarms you will get.
4. Is it published? A peer-reviewed paper describing the actual model, not a paper about a related question.
5. What does it tell you to do? A responsible tool prompts you to contact your team. It never tells you to change medication.

If an app cannot answer the first three, treat its risk score as a description of recent data dressed as a forecast.

Myths about predicting flares

"My watch caught my last flare, so it will catch the next one." One hit tells you nothing about the misses and false alarms. Count all three before you trust a rule, as Ana did.

"Research proves wearables predict IBD flares." Research shows wearable signals change on average weeks before flares, and that prediction is feasible. It has not shown a consumer device warning individuals with a known false-alarm rate.

"A high calprotectin means a flare is coming." It roughly triples the risk. Most people with a high reading in the PREdiCCt study still had no objective flare within two years. It means look closer, which your IBD team will decide how to do.

"If I tracked carefully enough I would see my IBS flares coming." The best real-time studies found stress and pain move together in the moment, but not in a way that predicts the next few hours or days. More data does not create a lead signal that is not there.

"Monitoring prevents flares." In the largest trial, telemonitoring cut clinic visits and admissions but not the number of flares. The benefit is faster, better-targeted response.

"If my tracker cannot predict flares, logging is a waste of time." Detection and documentation are the reasons to log, and both help your care even though neither is a forecast.

When to contact your IBD team, and when to see a doctor promptly

Contact your IBD team or GP, rather than waiting for a pattern to confirm itself, if you notice a sustained change from your normal over several days: more movements, looser stools, new urgency, night-time bowel movements, or a return of symptoms that previously meant a flare. Do not start, stop or change any medication on the strength of an app score, a wearable alert or a personal rule.

See a doctor promptly if you have blood in your stool, unexplained weight loss, a fever, bowel symptoms waking you at night, signs of anaemia such as breathlessness or a racing heart at rest, new symptoms starting after 50, or a family history of bowel cancer or IBD. Seek urgent care for severe or worsening abdominal pain, a swollen tender abdomen, frequent bloody diarrhoea, fainting or signs of dehydration. Our guide to when to go to hospital for a UC flare sets out those thresholds in detail.

The short version

No tracker, ring or watch can yet tell you that your flare is coming with a reliability you could plan around. In IBD, calprotectin in remission is the best-studied warning signal, and it raises risk rather than settling it. Wearable heart and sleep data shift on average in the weeks before flares, which is promising research, not a personal alarm. In IBS, we found no forecasting signal at all. Use your log to notice change early, to give your team numbers, and to test your own prodrome honestly. That is a smaller promise than "predict your next flare". It is the one the evidence can keep.